CN106501517A - Application of the material of SPARC protein in examination hepatocarcinoma test kit is prepared in detection serum - Google Patents
Application of the material of SPARC protein in examination hepatocarcinoma test kit is prepared in detection serum Download PDFInfo
- Publication number
- CN106501517A CN106501517A CN201611225837.1A CN201611225837A CN106501517A CN 106501517 A CN106501517 A CN 106501517A CN 201611225837 A CN201611225837 A CN 201611225837A CN 106501517 A CN106501517 A CN 106501517A
- Authority
- CN
- China
- Prior art keywords
- serum
- sparc protein
- blood plasma
- sparc
- examination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of new application for detecting the material of SPARC protein concentration.New application provided by the present invention is the application for detecting the material of SPARC protein concentration in preparation examination or auxiliary examination hepatocarcinoma product.It is demonstrated experimentally that SPARC protein can be used as the tumor markerses of hepatocarcinoma；Examination is carried out in the case of with normal artificial examination object, is judged to that the sensitivity of HCC patient is 82%, specificity is 0.89 for 93%, AUC；Examination is carried out in the case of with LC patient as examination object, is judged to that the sensitivity of HCC patient is 62%, specificity is 0.73 for 86%, AUC；SPARC protein can be used to diagnose AFP negative hepatocarcinoma；SPARC protein can also be combined with AFP for examination or auxiliary diagnosis HCC in normal person or LC patient.
Description
Technical field
The present invention relates to the material of SPARC protein is preparing examination liver in biological technical field, more particularly to detection serum
Application in cell carcinoma test kit.
Background technology
Hepatocarcinoma (hepatocellular carcinoma, HCC) is one of common malignant tumor, has higher sending out
Sick rate and mortality rate, every year about 650 000 people die from HCC, and its sickness rate has the trend for increasing.The disease is mainly in Southeast Asia,
Wherein there are about more than 50% and betide China.A situation arises is a multifactor, multistage process for hepatocarcinoma, B-mode liver
(hepatitis B virus, the HBV) chronic infection of scorching virus is important high risk factor, has the liver cirrhosis of hepatitis B background
(liver cirrhosis, LC) patient is the high-risk group that possible develop into hepatocarcinoma.5 years survival rates of hepatocarcinoma are poor at present,
Examination early hepatocarcinoma patient in the early screening of hepatocarcinoma, especially liver cirrhosis patient high-risk group, takes treatment to arrange in time
Apply, the survival rate of the patients with hepatocellular carcinoma for being secondary to hepatitis b virus infected can be improved.
At present HCC clinical diagnosises and state of illness monitoring etc. still depend on the imaging examinations such as B ultrasonic and combine blood serum designated object
The detection of alpha-fetoprotein (alpha-fetoprotein, AFP) level.And AFP is used as current HCC diagnosis and state of illness monitoring one
Topmost biomarker, its sensitivity are still undesirable.So, sensitive serum biomarkers in hepatocellular carcinoma thing is found, especially
Which can be applicable to the liver cancer patient of AFP negative, for diagnosing hepatocellular carcinoma extremely important.
SPARC protein is a kind of glycoprotein, adjusts cell growth by interacting with extracellular matrix and cytokine.
SPARC protein is close with the generation development relationship of tumor, there are some researches show SPARC protein overexpression (Le in HCC tissues
Bail,B.et al.Osteonectin/SPARC is overexpressed in human hepatocellular
carcinoma.J Pathol.1999).But the relation of every kind of albumen expression in peripheral blood and tissue is extremely complex,
Expression that cannot be simply from tissue derives its expression in peripheral blood, or even sometimes both expression
Level can be completely contrary.For example studies have reported that liver carboxylesterase 1 (CES1) albumen is organized in liver cancer patient
In significantly lower, and the albumen significantly raises (Na, K., et al., Human liver in liver cancer patient blood serum
carboxylesterase 1outperforms alpha-fetoprotein as biomarker to discriminate
hepatocellular carcinoma from other liver diseases in Korean patients.Int J
Cancer,2013).
Content of the invention
It is an object of the present invention to provide detecting the purposes of the material of SPARC protein concentration in serum or blood plasma.
The material for detecting SPARC protein concentration in serum or blood plasma that the present invention is provided is preparing examination or auxiliary diagnosis liver
Application in cell carcinoma product.
The material for detecting SPARC protein concentration in serum or blood plasma that the present invention is also provided is preparing examination or auxiliary diagnosis
Application in α-fetoprotein-negative hepatocarcinoma product.
In one embodiment of the invention, the hepatocarcinoma be specially be secondary to HBV infection have liver cirrhosis background
Hepatocarcinoma.
The SPARC protein behaviour SPARC protein.
In above-mentioned application, in the detection serum or blood plasma, the material of SPARC protein concentration includes detecting serum or blood plasma
Reagent and instrument needed for middle SPARC protein concentration.
In above-mentioned application, the reagent in the detection serum or blood plasma needed for SPARC protein concentration includes that SPARC protein resists
Body.
Second purpose of the present invention is to provide the material of SPARC concentration and detection serum or blood plasma in detection serum or blood plasma
The purposes of the material of middle alpha-fetoprotein concentration.
The invention provides detecting the material of SPARC concentration and alpha-fetoprotein in detection serum or blood plasma in serum or blood plasma
The material of concentration is preparing examination or the application in auxiliary diagnosis of hepatoma product.
In above-mentioned application, in the detection serum or blood plasma, the material of SPARC protein concentration includes detecting serum or blood plasma
Reagent and instrument needed for middle SPARC protein concentration；
Or, the material of alpha-fetoprotein concentration includes detecting alpha-fetoprotein in serum or blood plasma in the detection serum or blood plasma
Reagent and instrument needed for concentration.
In one embodiment of the invention, detect that the reagent in serum or blood plasma needed for alpha-fetoprotein concentration is AFPization
Luminescence method test kit is learned, instrument is Roche fully automatic electric chemical illumination immunity analysis instrument.
In above-mentioned application, the reagent in the detection serum or blood plasma needed for SPARC protein concentration includes that SPARC protein resists
Body.
3rd purpose of the invention is to provide a kind of examination or auxiliary diagnosis of hepatoma product.
The product that the present invention is provided, which includes the material of SPARC protein concentration in above-mentioned detection serum or blood plasma.
In one embodiment of the invention, the material for detecting SPARC protein concentration is anti-for SPARC protein
SPARC antibody used by body, specially ELISA (R＆D Systems companies, article No.：DSP00).It is of course also possible to be other types
Antibody or other can be used for detect SPARC protein concentration material.
In the present invention, the examination of the product or diagnosis are to liking liver cirrhosis (LC) patient or Healthy People.
In one embodiment of the invention, described liver cirrhosis (LC) patient is specially the liver cirrhosis patient of HBV infection.
The detection SPARC protein concentration concretely detects human serum or the SPARC protein concentration in blood plasma.
4th purpose of the invention is to provide a kind of examination or auxiliary diagnosis of hepatoma product.
The product that the present invention is provided, it include in above-mentioned detection serum or blood plasma the material of SPARC protein concentration and above-mentioned
The material of alpha-fetoprotein concentration in detection serum or blood plasma.
In the said goods, the product is test kit.
In order to find serum biomarkers in hepatocellular carcinoma thing, inventor to the tumor of the pairing of AFP negative liver cancer patient with
Cancer beside organism's interstitial fluid is identified that discovery SPARC protein is significantly raised in liver cancer patient tumor tissues interstitial fluid.Because group
It is the interface for connecting intracellular fluid and instrument for circulation of body fluid to knit interstitial fluid, and the result prompting SPARC protein is very likely to from hepatocarcinoma group
Knit and be secreted in blood by interstitial fluid.And then expression of the albumen in clinical serum sample is have detected,
It was found that its serum-concentration significantly increases in liver cancer patient, proposing SPARC protein can examine as the serum of AFP negative liver cancer patient
Disconnected mark, and can be with AFP Combining diagnosis hepatocarcinoma.
It is demonstrated experimentally that serum SPARC protein can be used as the tumor markerses of hepatocarcinoma (HCC).When with asymptomatic just
When ordinary person is as examination object, Receiver operating curve (receiver operating characteristic
Curve, ROC) analysis result shows that area under curve (Area Under roc Curve, AUC) reaches 0.89, sensitivity is
82%th, specificity is 93%；In the case of with LC patient as examination object, AUC=0.73, sensitivity are 62%, specificity
For 86%.When SPARC protein is used for diagnosing AFP negative liver cancer patient, with normal artificial examination object, AUC=0.88, sensitivity
For 78%, specificity is 93%；With LC patient as examination object, AUC=0.72, sensitivity are 61%, and specificity is 84%.
SPARC protein can also be combined with AFP for examination in LC patient or auxiliary diagnosis HCC.
Description of the drawings
Fig. 1 is that SPARC protein level dissipates in normal group (N), liver cirrhosis patient group (LC) and liver cancer patient group (HCC) serum
Point diagram.
Fig. 2 is SPARC protein level in normal group (N), liver cirrhosis patient group (LC) and liver cancer patient group (HCC) serum
ROC curve analysis result.
Fig. 3 is in normal group (N), AFP negative liver cirrhosis patient group (LC) and AFP negative liver cancer patient group (HCC) serum
The ROC curve analysis result of SAPRC protein levels.
Fig. 4 is that liver cirrhosis patient group (LC) and liver cancer patient group (HCC) SPARC are analyzed with the ROC curve of AFP Combining diagnosis
As a result.
Specific embodiment
Experimental technique used in following embodiments if no special instructions, is conventional method.
In following embodiments, material used, reagent etc., if no special instructions, commercially obtain.
Involved explanation of nouns in following embodiments：
Receiver Operating Characteristics (receiver (relative) operating characteristic, ROC) curve is anti-
The balance between sensitivity and specificity is reflected, area is important experimental accuracy index under ROC curve.Each examination is calculated respectively
Area (AUC) under the ROC curve that tests is compared, and the big person of area, the diagnostic value of test are big.
Sensitivity (True Positive Rate)：Actual ill and be correctly judged as ill percentage rate by test standard, sensitivity
It is the bigger the better, ideal sensitivity is 100%.
Specificity (true negative rate)：Actual disease-free and be correctly judged as disease-free percentage rate by test standard, specificity
It is the bigger the better, preferable specificity 100%.
Experimental technique used in following embodiments if no special instructions, is conventional method.
In following embodiments, material used, reagent etc., if no special instructions, commercially obtain.
The relation of SPARC protein and patient HCC in embodiment 1, serum
First, experiment material
Serum sample from：
Normal group：Normal person (N) 30；
LC patient's group：There is the liver cirrhosis patient (being not converted into hepatocarcinoma, LC) 35 of HBV chronic infection backgrounds；
HCC patient's group：(wherein 23 is that APF is cloudy the patients with hepatocellular carcinoma (HCC) 50 of HBV chronic infection backgrounds
Property).
Wherein, normal human serum is from physical examination of healthy population；Liver cirrhosis patient and patients with hepatocellular carcinoma are clinical definite disease
The serum sample of people.
2nd, in serum SPARC protein and patient HCC relation
SPARC protein level in serum sample to above-mentioned one carries out ELISA detections, and used kit is R＆D
Systems companies SPARC ELISA detection kit (article No.s：DSP00), concrete grammar is as follows：
1st, with diluent (being equipped with dilution buffer in test kit) 1：40 dilute serum samples, standard substance dilution ladder
Degree 50ng/ml, 25ng/ml, 12.5ng/ml, 6.25ng/ml, 3.13ng/ml, 1.56ng/ml, 0ng/ml, serum sample and mark
The each 100ul of quasi- product is added to and is surrounded by anti-96 orifice plates (test kit outfit), incubated at room 3 hours.
2nd, washed 6 times with washing liquid (being equipped with wash buffer in test kit), per 350 microlitres of hole, 1 minute every time.
3rd, add 200 microlitres of SPARC bis- anti-(carrying in test kit) per hole, 4 degree are incubated 1 hour.
4th, washed 6 times with washing liquid, per 350 microlitres of hole, 1 minute every time.
5th, 200 microlitre display substrates (in test kit be equipped with substrate solution) are added per hole, and room temperature lucifuge is incubated
Educate 30 minutes.
6th, add 50 microlitres of terminate liquids (stop solution are equipped with test kit) per hole.
7th, 450nm wavelength readings.
8th, standard curve is drawn by SPARC standard proteins concentration and its corresponding OD value.By each hole serum sample institute
The OD values for measuring, are fitted to the standard curve of SPARC using Excel softwares, calculate SPARC protein in each serum sample
Content.
9th, normal person (N) and patients with hepatocellular carcinoma (HCC), the liver cirrhosis patient with 16.0 softwares of SPSS respectively to health
(LC) and SPARC protein level carries out ROC curve analysis in patients with hepatocellular carcinoma (HCC) serum, and to liver cirrhosis patient (LC)
AFP is carried out with patients with hepatocellular carcinoma (HCC) to analyze with SPARC Combining diagnosis ROC curve.
ELISA detection knot of the SPARC protein expression in normal group, LC patient's group, the serum sample of HCC patient's group
Really：Mean concentration ± the standard deviation of normal group SPARC protein is 72.77 ± 51.79ng/ml, LC patient's group for 165.54 ±
88.47ng/ml, HCC patient group is 319.00 ± 192.66ng/ml.Statistics are carried out to SPARC protein content in each group sample
Analysis (Mann-Whitney test), finds serum SPARC protein in normal group and HCC patient group (p<And LC 0.0001)
Patient's group and HCC patient's group (p=0.0002) have significant difference (Fig. 1).
With normal group as matched group, HCC patient's group is disease group, carries out ROC curve point to SPARC protein level in serum
Analysis, area under curve AUC=0.89 (as shown in A in Fig. 2), it is 93% that sensitivity is 82%, specificity；It is right with LC patient's group
According to group, HCC patient's group is disease group, and AUC=0.73 (as shown in B in Fig. 2), sensitivity are that 62%, specificity is 86%.
From the above results, in serum, SPARC protein can be used as normal person and be entered with HCC patient with HCC patient and LC
The potential mark of row Distinguishing diagnosis.
Carry out normal person and HCC patient Distinguishing diagnosis when, if SPARC protein concentration is more than or equal in human serum to be measured
130.72ng/ml, then the artificial or candidate to be measured is HCC patient.
Carry out LC patient and HCC patient Distinguishing diagnosis when, if SPARC protein concentration is more than or equal in human serum to be measured
261.80ng/ml, then the artificial or candidate to be measured is HCC patient.
Maximum youden index corresponding threshold value of the concentration threshold of above-mentioned two Distinguishing diagnosis for ROC curve, with normal person
As a example by the Distinguishing diagnosis of HCC patient, youden index and corresponding threshold value refer to table 1 (maximum youden index and corresponding threshold value runic
Mark).
Threshold value of the table 1 with normal group as matched group, sensitivity, specificity and youden index
3rd, application of the SPARC protein in the HCC patient of detection AFP negative in serum
By the normal person in above-mentioned, the liver cirrhosis (LC) of 17 AFP negatives for having HBV chronic infection backgrounds and 23
Hepatocarcinoma (HCC) the patients serum sample of AFP negative is detected according to above-mentioned two method.
As a result the serum-concentration mean+SD of normal group SPARC protein be 72.77 ± 51.79ng/ml, 17
LC patient's group of AFP negative is 152.25 ± 94.30ng/ml, HCC patient's group of 23 AFP negatives for 308.62 ±
196.04ng/ml.
With AFP negative (AFP<20ng/ml) HCC patient group be disease group, normal group is matched group, to serum in
SPARC protein level carries out ROC curve analysis, area under curve AUC=0.88 (Fig. 3 A), and sensitivity is 78%, and specificity is
93%.With HCC patient's group of AFP negative as disease group, AFP negative liver cirrhosis patient group is matched group, to SPARC eggs in serum
White level carries out ROC curve analysis, area under curve AUC=0.72 (Fig. 3 B), and sensitivity is 61%, and specificity is 84%.Say
Bright SPARC protein can be used for the liver cancer patient of Distinguishing diagnosis AFP negative.
During the Distinguishing diagnosis of the HCC patient for carrying out normal person and AFP negative, if SPARC protein concentration in human serum to be measured
It is more than or equal to 136.18ng/ml, then the artificial or candidate to be measured is HCC patient.
Carry out the LC patient of AFP negative and the HCC patient of AFP negative Distinguishing diagnosis when, if SPARC in human serum to be measured
Protein concentration is more than or equal to 247.36ng/ml, then the artificial or candidate to be measured is HCC patient.
Maximum youden index corresponding threshold value of the concentration threshold of above-mentioned two Distinguishing diagnosis for ROC curve.
4th, the application of SPARC protein and AFP albumen in detection HCC patient
AFP serum protein concentrations detection methods：Using Roche fully automatic electric chemical illumination immunity analysis instrument, using AFPization
The detection of luminescence method test kit is learned, detailed step is with reference to instrument description.
The serum-concentration of normal group AFP albumen is respectively less than 20ng/ml, and LC patient's group is 2260.6 ± 12582.0ng/ml,
HCC patient's group is 13626.6 ± 47251.9ng/ml.The blood that SPARC protein concentration is organized in normal group, LC patient's group, HCC patient
ELISA testing results in final proof sheet：Mean concentration ± the standard deviation of normal group SPARC protein is 72.77 ± 51.79ng/
Ml, LC patient group is 165.54 ± 88.47ng/ml, and HCC patient's group is 319.00 ± 192.66ng/ml.
Statistical analysis (Mann-Whitney test) are carried out to SPARC protein in each group sample and AFP protein concentrations,
It was found that serum SPARC protein and AFP protein concentrations are in normal group and HCC patient group (p<And LC patient's group and HCC 0.0001)
Patient's group (p=0.0002) has significant difference.
The common standard foundation binary Logistic regression Calculation result for judging SPARC protein and AFP albumen, distinguishes HCC
With normal group specific formula for calculation it is：P=1/ (1+e-(-2.415+0.018*SPARC+0.002*AFP)), when p is more than or equal to 0.643, sentence
Break as HCC；Distinguish HCC and LC computing formula be：P=1/ (1+e-(-1.498+0.008*SPARC+0.000016*AFP)), when p is more than or equal to
When 0.633, it is judged as HCC.
With 16.0 softwares of SPSS respectively to normal person (N) and patients with hepatocellular carcinoma (HCC), liver cirrhosis (LC) and hepatocyte
Cancer patient (HCC) carries out the ROC curve analysis that AFP and SPARC is used in combination diagnosis HCC.
With normal group as matched group, HCC patient's group is disease group, and serum SPARC protein and AFP albumen are used in combination differentiation
Area under curve AUC=0.93 (as shown in A in Fig. 4) of diagnosis HCC patient, it is 97% that sensitivity is 86%, specificity；With LC
Patient's group is matched group, and HCC patient's group is disease group, and both are used in combination the AUC=0.78 of Distinguishing diagnosis HCC patient (such as Fig. 4
Shown in middle B), it is 84% that sensitivity is 67%, specificity.
From the above results, in serum SPARC protein and AFP albumen can be used as normal person and HCC patient and LC with
HCC patient carries out the potential mark of Distinguishing diagnosis.
The above results are summarized in table 2 and table 3, illustrate SPARC protein, AFP albumen and its use in conjunction for hepatocyte
Cancer patient and normal person or the effect of LC patient's Differential Diagnosiss.
2 SPARC protein of table and AFP albumen Distinguishing diagnosis normal persons and patients with hepatocellular carcinoma effect compare (SPARC or
SPARC and AFP is used in combination effect better than AFP)
3 SPARC protein of table and AFP albumen Distinguishing diagnosis liver cirrhosis and patients with hepatocellular carcinoma effect compare (SPARC or
SPARC and AFP is used in combination effect better than AFP)
From the above results, in serum, SPARC protein can be used as normal person and be entered with HCC patient with HCC patient and LC
The potential mark of row Distinguishing diagnosis.
Sequence table
<110>Beijing Proteome Research Center
<120>Application of the material of SPARC protein in examination hepatocarcinoma test kit is prepared in detection serum
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 303
<212> PRT
<213>Artificial sequence
<220>
<223>
<400> 1
Met Arg Ala Trp Ile Phe Phe Leu Leu Cys Leu Ala Gly Arg Ala Leu
1 5 10 15
Ala Ala Pro Gln Gln Glu Ala Leu Pro Asp Glu Thr Glu Val Val Glu
20 25 30
Glu Thr Val Ala Glu Val Thr Glu Val Ser Val Gly Ala Asn Pro Val
35 40 45
Gln Val Glu Val Gly Glu Phe Asp Asp Gly Ala Glu Glu Thr Glu Glu
50 55 60
Glu Val Val Ala Glu Asn Pro Cys Gln Asn His His Cys Lys His Gly
65 70 75 80
Lys Val Cys Glu Leu Asp Glu Asn Asn Thr Pro Met Cys Val Cys Gln
85 90 95
Asp Pro Thr Ser Cys Pro Ala Pro Ile Gly Glu Phe Glu Lys Val Cys
100 105 110
Ser Asn Asp Asn Lys Thr Phe Asp Ser Ser Cys His Phe Phe Ala Thr
115 120 125
Lys Cys Thr Leu Glu Gly Thr Lys Lys Gly His Lys Leu His Leu Asp
130 135 140
Tyr Ile Gly Pro Cys Lys Tyr Ile Pro Pro Cys Leu Asp Ser Glu Leu
145 150 155 160
Thr Glu Phe Pro Leu Arg Met Arg Asp Trp Leu Lys Asn Val Leu Val
165 170 175
Thr Leu Tyr Glu Arg Asp Glu Asp Asn Asn Leu Leu Thr Glu Lys Gln
180 185 190
Lys Leu Arg Val Lys Lys Ile His Glu Asn Glu Lys Arg Leu Glu Ala
195 200 205
Gly Asp His Pro Val Glu Leu Leu Ala Arg Asp Phe Glu Lys Asn Tyr
210 215 220
Asn Met Tyr Ile Phe Pro Val His Trp Gln Phe Gly Gln Leu Asp Gln
225 230 235 240
His Pro Ile Asp Gly Tyr Leu Ser His Thr Glu Leu Ala Pro Leu Arg
245 250 255
Ala Pro Leu Ile Pro Met Glu His Cys Thr Thr Arg Phe Phe Glu Thr
260 265 270
Cys Asp Leu Asp Asn Asp Lys Tyr Ile Ala Leu Asp Glu Trp Ala Gly
275 280 285
Cys Phe Gly Ile Lys Gln Lys Asp Ile Asp Lys Asp Leu Val Ile
290 295 300
Claims (10)
1. detect the material of SPARC protein concentration in serum or blood plasma in examination or auxiliary diagnosis of hepatoma product is prepared
Application.
2. detect that the material of SPARC protein concentration in serum or blood plasma is thin in preparation examination or auxiliary diagnosis α-fetoprotein-negative liver
Application in born of the same parents' cancer product.
3. application according to claim 1 and 2, it is characterised in that：SPARC protein concentration in the detection serum or blood plasma
Material include detecting the reagent and instrument in serum or blood plasma needed for SPARC protein concentration.
4. according to arbitrary described application in claim 1-3, it is characterised in that：SPARC eggs in the detection serum or blood plasma
White reagent needed for concentration includes SPARC protein antibody.
5. detect that the material of SPARC concentration and the material for detecting alpha-fetoprotein concentration in serum or blood plasma are being made in serum or blood plasma
Application in standby examination or auxiliary diagnosis of hepatoma product.
6. application according to claim 5, it is characterised in that：SPARC protein concentration in the detection serum or blood plasma
Material includes detecting the reagent and instrument in serum or blood plasma needed for SPARC protein concentration；
Or, the material of alpha-fetoprotein concentration includes detecting alpha-fetoprotein concentration in serum or blood plasma in the detection serum or blood plasma
Required reagent and instrument.
7. application according to claim 6, it is characterised in that：SPARC protein concentration institute in the detection serum or blood plasma
The reagent for needing includes SPARC protein antibody.
8. a kind of examination or auxiliary diagnosis of hepatoma product, it are included in the arbitrary middle detection serum of claim 1-4 or blood plasma
The material of SPARC protein concentration.
9. a kind of examination or auxiliary diagnosis of hepatoma product, it are included in the arbitrary middle detection serum of claim 1-4 or blood plasma
The material of alpha-fetoprotein concentration in the material of SPARC protein concentration and the arbitrary detection serum of claim 5-7 or blood plasma.
10. product according to claim 8 or claim 9, it is characterised in that：
The product is test kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611225837.1A CN106501517B (en) | 2016-12-27 | 2016-12-27 | Detect application of the material of SPARC protein in serum in examination hepatocellular carcinoma kit is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611225837.1A CN106501517B (en) | 2016-12-27 | 2016-12-27 | Detect application of the material of SPARC protein in serum in examination hepatocellular carcinoma kit is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106501517A true CN106501517A (en) | 2017-03-15 |
| CN106501517B CN106501517B (en) | 2018-05-08 |
Family
ID=58334441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611225837.1A Active CN106501517B (en) | 2016-12-27 | 2016-12-27 | Detect application of the material of SPARC protein in serum in examination hepatocellular carcinoma kit is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106501517B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107037210A (en) * | 2017-04-05 | 2017-08-11 | 北京蛋白质组研究中心 | Application of the THBS2 Protein Detections thing in diagnosis of hepatoma kit is prepared |
| CN107102147A (en) * | 2017-04-05 | 2017-08-29 | 北京蛋白质组研究中心 | THBS2 Protein Detections thing is preparing the application during prognosis of HCC assesses kit |
| CN111656193A (en) * | 2017-12-19 | 2020-09-11 | 北欧生物科技公司 | SPARC assay |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102695716A (en) * | 2009-07-14 | 2012-09-26 | 独立行政法人产业技术综合研究所 | Sugar chain marker as measure of disease conditions of hepatic diseases |
| CN103221062A (en) * | 2010-06-03 | 2013-07-24 | 阿布拉西斯生物科学有限责任公司 | Peripheral blood SPARC antibodies and uses thereof |
| CN103874770A (en) * | 2011-08-08 | 2014-06-18 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarker compositions and methods |
| CN104777305A (en) * | 2014-08-27 | 2015-07-15 | 北京蛋白质组研究中心 | Use of stress-induced-phosphoprotein1 (STIP1) in preparation of product for hepatocellular carcinoma screening |
| CN105316405A (en) * | 2003-07-17 | 2016-02-10 | 环太平洋生物技术有限公司 | Markers for detection of gastric cancer |
-
2016
- 2016-12-27 CN CN201611225837.1A patent/CN106501517B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105316405A (en) * | 2003-07-17 | 2016-02-10 | 环太平洋生物技术有限公司 | Markers for detection of gastric cancer |
| CN102695716A (en) * | 2009-07-14 | 2012-09-26 | 独立行政法人产业技术综合研究所 | Sugar chain marker as measure of disease conditions of hepatic diseases |
| CN103221062A (en) * | 2010-06-03 | 2013-07-24 | 阿布拉西斯生物科学有限责任公司 | Peripheral blood SPARC antibodies and uses thereof |
| CN103874770A (en) * | 2011-08-08 | 2014-06-18 | 卡里斯生命科学卢森堡控股有限责任公司 | Biomarker compositions and methods |
| CN104777305A (en) * | 2014-08-27 | 2015-07-15 | 北京蛋白质组研究中心 | Use of stress-induced-phosphoprotein1 (STIP1) in preparation of product for hepatocellular carcinoma screening |
Non-Patent Citations (1)
| Title |
|---|
| 陈科济等: "肝细胞癌组坌RSPARC表达及其临床意义", 《中国癌症杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107037210A (en) * | 2017-04-05 | 2017-08-11 | 北京蛋白质组研究中心 | Application of the THBS2 Protein Detections thing in diagnosis of hepatoma kit is prepared |
| CN107102147A (en) * | 2017-04-05 | 2017-08-29 | 北京蛋白质组研究中心 | THBS2 Protein Detections thing is preparing the application during prognosis of HCC assesses kit |
| CN107102147B (en) * | 2017-04-05 | 2019-09-13 | 北京蛋白质组研究中心 | Application of the THBS2 Protein Detection object in preparation prognosis of HCC assessment kit |
| CN111656193A (en) * | 2017-12-19 | 2020-09-11 | 北欧生物科技公司 | SPARC assay |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106501517B (en) | 2018-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pal et al. | Evaluation of a novel quantitative test for glucose-6-phosphate dehydrogenase deficiency: bringing quantitative testing for glucose-6-phosphate dehydrogenase deficiency closer to the patient | |
| Degos et al. | Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study) | |
| Kelleher et al. | Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index | |
| CN106405104B (en) | A kind of new cirrhosis or hepatic fibrosis markers | |
| Wade et al. | WHO multicenter evaluation of FACSCount CD4 and Pima CD4 T-cell count systems: instrument performance and misclassification of HIV-infected patients | |
| CN106501517B (en) | Detect application of the material of SPARC protein in serum in examination hepatocellular carcinoma kit is prepared | |
| CN108613977B (en) | N-terminal brain natriuretic peptide precursor detection kit | |
| CN102081100B (en) | Liver cancer multi-marker micro-array kit as well as preparation method and application thereof | |
| CN109557311A (en) | The testing product and its application of diagnosis of colorectal carcinoma marker and colorectal cancer | |
| Howanitz et al. | Practices for identifying and rejecting hemolyzed specimens are highly variable in clinical laboratories | |
| Boyko et al. | Latent class analysis of the metabolic syndrome | |
| Addissouky | Detecting liver fibrosis by recent reliable biomarkers in viral hepatitis patients | |
| CN108133754B (en) | The forecasting system of bleeding risk after a kind of thrombolysis | |
| CN105021827B (en) | The application in preparation detection inflammation and fibrosis product of the material of detection Serum angiogenin sample albumen 2 content | |
| CN108048525A (en) | The kit of bleeding risk after a kind of detection thrombolysis | |
| CN108107221A (en) | Purposes and kit of the specific agglutinin combination in terms of the test carrier to differentiate ovarian epithelial carcinoma is prepared | |
| CN107037210A (en) | Application of the THBS2 Protein Detections thing in diagnosis of hepatoma kit is prepared | |
| CN102175839A (en) | Detection method of IgG (immunoglobulin G) core fucosylation level and use thereof | |
| Rubin et al. | Accuracy of three dry-chemistry methods for lipid profiling and risk factor classification | |
| Dima | Point of care testing (POCT) present and future | |
| CN106153923B (en) | Predict that glutamic-pyruvic transaminase is less than the system of the Patients with Chronic Hepatitis B inflammation degree of two times of normal upper limits | |
| CN110687289B (en) | Application of FGL2 protein as malaria infection marker | |
| CN111596068A (en) | Application of Utrophin in early warning, diagnosis and prognosis evaluation of POP (Point of Presence) and product | |
| Arikan et al. | NeuMoDx random access molecular diagnostic system for detection and quantification of hepatitis B virus in clinical samples | |
| Kwon et al. | The assessment of blood glucose distribution according to the fasting state and glycemic control indicators for diabetes screening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220314 Address after: 102206 No. 38, Life Science Park Road, Changping District, Beijing Patentee after: BEIJING PROTEOME RESEARCH CENTER Patentee after: Academy of military medicine, PLA Academy of Military Sciences Address before: 102206 38 shengshengyuan Road, Changping District, Beijing Patentee before: BEIJING PROTEOME RESEARCH CENTER |